Actavis and Zydus settle with Supernus over seizure drug
Speciality pharmaceutical company Supernus has settled patent disputes over Trokendi XR (topiramate), a treatment for partial seizures, with US-based Zydus Pharmaceuticals and Actavis Laboratories.
The settlements were made official early last week in an announcement by Supernus.
Supernus' patent litigation against Zydus and Actavis arose in March last year when the companies filed for Abbreviated New Drug Applications with the Food and Drug and Administration seeking to market generic versions of Trokendi XR.
Following the agreement with Zydus, Supernus has permitted Zydus to sell a generic version of the drug from January 1, 2023, or earlier under certain circumstances.
Supernus has entered into a binding term sheet, a document which sets out certain terms of a transaction agreed in principle between parties, with Actavis, which is now a subsidiary of Teva.
Actavis will also be permitted to market its generic starting in January 2023.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk